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Short Report
Lack of effect of ketamine on cortical
glutamate and glutamine in healthy
volunteers: a proton magnetic resonance
spectroscopy study
Matthew J Taylor1, Eleanor R Tiangga1, Roı´sı´n Nı´ Mhuircheartaigh2
and Philip J Cowen1
Abstract
Ketamine is a N-methyl-D-aspartic acid (NMDA) antagonist that has been associated with temporary clinical improvement in patients with depression.
Studies using magnetic resonance spectroscopy (MRS) have shown that major depression is associated with decreased levels of glutamate and
glutamine (Glx) in the anterior cingulate cortex, which normalize with clinical recovery. The present study aimed to test whether a ketamine infusion
would increase cortical Glx levels in healthy volunteers. Healthy volunteers received an intravenous infusion of ketamine (0.5mg kg1, n¼ 8) or saline
(n¼ 9) over 40 minutes. MRS measurements were obtained at baseline, during, and at the end of the infusion. The infusion of ketamine had significant
effects on mental state but there was no effect of ketamine on the levels of Glx (F3,39¼ 1.70, p¼ 0.18) or glutamate (F3,39¼ 48, p¼ 0.70). This study
suggests that the gradual infusion of low-dose ketamine in antidepressant doses not cause changes in cortical glutamate or glutamine in healthy
volunteers that are visible by proton MRS.
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Introduction
Ketamine is a N-methyl-D-aspartic acid (NMDA) antagonist
and clinically used anaesthetic that has been employed in sub-
anaesthetic doses to bring about temporary clinical improve-
ment in patients with treatment-resistant depression (Berman
et al., 2000; Zarate et al., 2006). In preclinical studies, low-dose
ketamine increases glutamate outﬂow in the prefrontal cortex
(Moghaddam et al., 1997). This is thought to reﬂect a loss of
inhibitory tone from GABAergic interneurons on cortical pyra-
midal neurons, since NMDA receptors preferentially drive the
interneurons in awake cortex (Homayoun et al., 2007).
Proton magnetic resonance spectroscopy (MRS) is a tech-
nique that allows safe non-invasive imaging of brain chemicals,
including glutamate, in vivo. Using MRS, patients with major
depressionhave been found tohave decreased levels of glutamate
and a combinedmeasure of glutamate and glutamine (Glx) in the
anterior cingulate cortex (ACC) (Auer et al., 2000; Hasler et al.,
2007). Levels of Glx appear to normalize with clinical recovery
(Bhagwagar et al., 2008; Hasler et al., 2005; Taylor et al., 2009).
This raised the hypothesis that ketamine might act to normalize
decreasedGlx. In support of this, loading doses of ketamine have
been associated with transient increases in glutamine in the ACC
of healthy volunteers (Rowland et al., 2005).
The present study aimed to test whether a low-dose keta-
mine infusion, similar to that used in treatment studies in
depressed patients, would increase cortical Glx levels in
healthy volunteers.
Methods and materials
We studied 17 healthy volunteers (11 male, 6 female; see
Table 1) who were free of any Axis I diagnosis by the
Standardized Clinical Interview for Diagnostic and
Statistical Manual of Mental Disorders-IV (First et al.,
1997) and who had not taken psychoactive medications for
at least three months before commencing the study. Four
volunteers (1 ketamine, 3 control) had previously taken part
in a placebo-controlled research study of short-term citalo-
pram. They were also free of any physical illness and taking
no other medications except the oral contraceptive pill. After
complete description of the study, all participants gave full
informed written consent to the study, which was approved
by the local ethics committee. Participants received an hono-
rarium for their participation.
Volunteers received an intravenous infusion of ketamine
(0.5mg kg1, n¼ 8) or saline (n¼ 9) over 40 minutes in a
parallel group design. Baseline personality ratings were
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measured using the Eysenck Personality Questionnaire
(EPQ), Schizotypal Personality Questionnaire (SPQ) (Raine
1991), and Oxford–Liverpool Inventory of Feelings and
Experiences (OLIFE) (Mason et al., 2006) in case such factors
were associated with response to ketamine. Mental state
eﬀects of infusion were measured by pre- and post-infusion
ratings using the Clinician Administered Dissociative States
Scale (CADSS), Hamilton Depression Rating Scale
(HAMD), Young Mania Rating Scale (YMRS), and Brief
Psychiatric Rating Scale (BPRS). The rater was not blind to
infusion type.
Imaging
Scanning was performed on a 3T Varian INOVA system with
a head optimized gradient coil (Tesla Engineering,
Storrington, UK) and a head-only transmit/receive quadra-
ture birdcage RF coil. MRS measurements were obtained at
baseline, during (two measurements), and at the end of the
infusion. PRESS and PRESS-J measurements were taken
from a 30 20 20mm voxel placed in the ACC and
medial prefrontal cortex positioned manually by reference
to an axial T1-weighted gradient-echo image (Figure 1).
Acquisitions similarly acquired and analysed have provided
good test–retest reliability for both Glx and glutamate on this
system (CV< 10% in both cases, unpublished data).
PRESS data with water suppression (TE 26ms, TR 3 s, 64
averages), and without (TE 26ms, TR 3 s) were acquired.
PRESS-J data (Hurd et al., 2004) were similarly acquired for
glutamate quantitation (TE 35–185ms, 10-ms increments;
water-suppressed data, total acquisitions¼ 128; non-water sup-
pressed data, total acquisitions¼ 16; TR¼ 3 s). T1-weighted
structural images of whole brain were acquired with 2mm3
voxel resolution. PRESS data were analysed with LCModel
software (Provencher, 2001), using the non-water suppressed
data for eddy current correction and water referencing, calcu-
lating metabolite concentrations for Glx, myo-inositol, choline
and N-acetylaspartate relative to creatine in conventional fash-
ion using metabolite basis spectra and simulated lipid and mac-
romolecule components. A criterion was set to reject
metabolite estimates with Crame´r–Rao lower bound >20%;
no estimates were excluded for that reason.
Measurements from the PRESS-J spectra were performed
using AMARES (Advanced method for accurate, robust and
eﬃcient spectral ﬁtting) (Vanhamme et al., 1997). PRESS-J
spectra were zero-order phased, apodized with a 5-Hz
Gaussian ﬁlter, and summed before analysis, and glutamate
levels measured relative to creatine. FMRIB’s Automated
Segmentation Tool (FAST) (Zhang et al., 2001) was employed
to segment the structural brain images into grey matter, white
matter, and CSF, to allow estimation of voxel composition.
Statistical analysis
Statistical analyses were performed in SPSS version 15 using
the general linear model with group and time as factors. A
multivariate analysis of all available MRS measures (Glx,
glutamate, myo-inositol, choline and N-acetylaspartate) was
performed using Wilks’ lambda. The primary outcome mea-
sures of change in Glx and glutamate were tested by univar-
iate analysis. Voxel grey matter content and age were included
as covariates since an eﬀect of voxel composition on Glx
measures is well established (Mclean and Barker, 2006) and
an eﬀect of age has been described (Raininko and Mattsson,
2010). To investigate the sensitivity of the results to the use of
creatine as reference, the analyses were repeated using mea-
sures referenced to tissue water. Exploratory comparisons of
other measures between groups were performed by t-test or
chi-square test as appropriate. All analyses were two-tailed.
Results
The groups were demographically similar at baseline (Table 1).
The 40-minute continuous infusion of ketamine had signiﬁcant
eﬀects on mental state as reﬂected in increased scores on both
CADSS (23.1 vs 0.8, p< .05) and BPRS (9.5 vs 0.2, p< .05)
compared to placebo. HAMD scores were also signiﬁcantly
increased, but remained in the normal range (3.9 vs 0.8, p< .05).
In contrast, there was no signiﬁcant diﬀerence between
groups in concentrations of cortical Glx (F3,39¼ 1.70,
p¼ 0.18) or glutamate (F3,39¼ .48, p¼ 0.70) in the anterior
cingulate cortex (Figure 2). This lack of eﬀect of ketamine
was observed whether levels were referenced to creatine or
tissue water; nor were eﬀects seen measuring Glx relative to
glutamate (Figure 2). No signiﬁcant eﬀects on any other MRS
measure were observed (F15,97¼ .74, p¼ .7). The voxel
contained an average 61% grey matter. Results were not sen-
sitive to the removal of age or grey matter as covariates.
Table 1. Group characteristics. Mean values with standard deviation
unless otherwise stated.
Saline (n¼ 9) Ketamine (n¼ 8)
Age 23.9 (1.7) 24.9 (4.7)
Gender 6 male, 3 female 5 male, 3 female
EPQ N 7.1 (5.1) 5.6 (3.4)
P 3.4 (3.1) 2.4 (2.2)
E 15.1 (2.1) 15.5 (4.2)
L 7.7 (2.3) 7.4 (3.0)
SPQ 4.9 (8.2) 6.1 (6.4)
OLIFE UnEx (2.1) 0.9 (1.6)
CogDis 4.1 (4.1) 3.9 (2.2)
IntAn 3.1 (2.4) 3.6 (1.8)
ImpNon 5.0 (1.7) 6.6 (4.0)
CADSS pre 0 (0) 0.1 (0.4)
post 0.8 (1.1) 23.1 (8.6)*
HAMD pre 0.2 (0.4) 0.1 (0.4)
post 0.8 (1.1) 3.9 (2.7)*
YMRS pre 0 (0) 0 (0)
post 0.1 (0.3) 2.0 (2.7)
BPRS pre 0.2 (0.7) 0.2 (0.7)
post 0.2 (0.7) 9.5 (6.2)*
EPQ¼ Eysenck Personality Questionnaire – scales Neuroticism (N), Psychoticism (P),
Extroversion (E), Lie (L); SPQ¼ Schizotypal Personality Questionnaire; OLIFE¼Oxford-
Liverpool Inventory of Feelings and Experiences – subscales; UnEx¼Unusual
Experiences; CogDis¼ Cognitive Disorganization; IntAn¼ Introvertive Anhedonia;
ImpNon¼ Impulsive Nonconformity; CADSS¼ Clinician Administered Dissociative
States Scale; HAMD¼Hamilton Depression Rating Scale; YMRS¼ Young Mania Rating
Scale; BPRS¼ Brief Psychiatric Rating Scale.
*p< 0.05, t-test.
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No signiﬁcant associations between subjective measures and
MRS measures were observed.
Discussion
This study suggests that the gradual infusion of low-dose
ketamine does not cause changes visible with proton MRS
in cortical glutamate or glutamine in healthy volunteers.
This is in contrast to studies in animals where administration
of sub-anaesthetic doses of ketamine has been shown to
increase levels of glutamate in prefrontal cortex as measured
by microdialysis (Moghaddam et al., 1997). However, MRS
will not distinguish between glutamate in the synapse and that
in other tissue compartments, for example, glia and pre-
synaptic nerve terminals. Hence an increase in glutamate
release without an elevation in overall tissue levels might
not be detected by proton MRS, although such an eﬀect
might be demonstrated using alternative techniques such as
carbon-13 spectroscopy.
As noted in the Introduction, Rowland et al. (2005)
observed a small increase in glutamine levels in ACC during
administration of a loading dose of ketamine (0.27mg/kg
over 10min) but not during a two-hour maintenance infusion.
It is possible, therefore, that change in glutamate/glutamine
might be both transient and very sensitive to ketamine dosing
regimes. We employed a regime that has been found to pro-
duce antidepressant eﬀects in depressed patients, but the
levels of ketamine achieved would probably be lower than
those seen following certain target-controlled infusion tech-
niques (e.g. Corlett et al., 2006). In addition Rowland et al.
used MRS at 4T, which, unlike the present study, permitted
separate delineation of glutamine and may therefore have
permitted a more accurate measure of this neurochemical.
The dose of ketamine that we administered produced
robust changes in mental state which were particularly appar-
ent on the CADSS. The extent of these subjective changes was
similar to that reported in other ketamine studies in healthy
volunteers (Krystal et al., 1994) and also in depressed patients
receiving ketamine for its antidepressant eﬀect (Diazgranados
et al., 2010). Thus ketamine administration produced clear
changes in subjective mental state in the absence of measur-
able changes in glutamate and Glx as measured by MRS.
Figure 1. Voxel position and sample spectra from PRESS (top), PRESS-J (bottom) acquisitions. Peaks indicated for creatine (Cr), myo-inositol (mI),
choline (Cho), glutamateþ glutamine (Glx), N-acetylaspartate (NAA), and glutamate (Glu).
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There are several potential limitations to this study.
Changes would not have been identiﬁed if they occurred in
regions outside the voxel measured. At 3T, in this study, glu-
tamine was not resolved separately. While increased gluta-
mine should have been reﬂected in increased Glx,
particularly given the stable glutamate measures, at this
sample size, small changes cannot be excluded. Because the
eﬀect of ketamine on glutamatergic function is thought to be
mediated via GABAergic interneurons (Homayoun et al.,
2007), future studies could also include gamma-aminobutyric
acid (GABA) measurements. Higher ﬁeld strength may allow
for better diﬀerentiation and measurement of glutamate, glu-
tamine, and GABA. It may also be possible, of course, that
studies in depressed patients, who would be predicted to have
low Glx levels prior to treatment, would be able to demon-
strate clearer MRS eﬀects following ketamine treatment.
Ketamine treatment of depression may have eﬀects after com-
pletion of the infusion when clinical beneﬁts can be observed
(Zarate et al., 2006).
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